Abstract
We studied the histological and ultrastructural changes in the liver and alterations in the liver test results before, during, and after treatment with human interferon-β from five patients with hepatitis B e antigen-positive chronic active hepatitis. A daily dose of 3×106 to 6×106 units of interferon-β was given intravenously for four weeks. The total index of periportal and portal inflammation, intralobular degeneration, and focal necrosis before treatment was decreased significantly six months after treatment (P<0.05). Ultrastructurally, the structure of endoplasmic reticulum was irregularly shaped or fragmentally decreased during treatment, but these disappeared six or 12 months after treatment. Glycogen particles diminished greatly during treatment. The alanine aminotransferase concentrations in these patients increased during treatment. Serum albumin and cholinesterase levels decreased significantly at the fourth week of treatment (P<0.01) and at the third day (P<0.01) to the second week (P<0.05) of treatment, respectively. These results suggest that interferon-β injures endoplasmic reticulum and glycogen areas and damages the cholinesterase activity in the early stage of treatment and protein synthesis in patients with hepatitis B e antigen-positive chronic active hepatitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TG: Effect of human leukocyte on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295:517–522, 1976
Caselmann WH, Eisenburg J, Hofschneider PH, Rajen K: α-and β-Interferon in chronic active hepatitis B. A pilot trial of short-term combination therapy. Gastroenterology 96:449–455, 1989
Hoofnagle JH, Peters M, Mulien KD, Jones B, Rustigi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones A: Randomized controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318–1325, 1988
Weimer W, Heijtink RA, Schalm SW, Masurel N, Schellekens H: Double-blind study of leukocyte interferon administration in chronic HBeAg positive hepatitis. Lancet 1:336–338, 1980
Dooley JS, Davis GL, Peters M, Waggner JG, Goodman Z, Hoofnagle JH: Pilot study of recombinant human α-interferon for chronic type B hepatitis. Gastroenterology 90:150–157, 1986
Dusheiko GM, Di Bisceglie A, Bowyer S, Sacks E, Kew MG: Prolonged recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 5:556–560, 1985
Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, Robinson WS, Merigan TC: Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis 143:772–783, 1981
Itoh S, Matsuo S, Shimoji K, Oda T, Sasaki I: The effect of α-interferon on the liver in a patient with hairy cell leukemia: light and electron microscopic studies. Am J Gastroenterol 84:942–947, 1989
Kaplan PM, Greeman RL, Gerin JL, Purcell RH, Robinson WS: DNA polymerase associated with human hepatitis B antigen. J Biol 12:995–1005, 1973
DeGroote J, Desmet VJ, Gedick P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uelinger E, Wepler W: A classification of chronic hepatitis. Lancet 2:626–628, 1968
Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435, 1981
Moochhala SM, Renton KW, Stebbing N: Induction and depression of cytochrome P-450-dependent mixed-function oxidase by a cloned consensus α-interferon (INF-αCON1) in the hamster. Biochem Pharmacol 38:439–447, 1989
Marutani K: Changes in hepatic function and ultrastructures of hepatocytes during treatment with interferon β and a streptococcal preparation (OK-432) in patients with HBeAg-positive chronic hepatitis. Saitama Med J 18:279–292, 1991
Saito M, Ebina T, Koi M, Yamaguchi T, Kawade Y, Ishida N: Induction of interferon-γ in mouse spleen cells by OK-432, a preparation ofstreptococcus pyogenes. Cell Immunol 68:187–192, 1982
Matsubara S, Suzuki F, Ishida N: Induction of immune interferon in mice treated with a bacterial immunopotentiator, OK-432. Cancer Immunol Immunother 6:41–45, 1979
Uchida A, Nicksche M:In vitro augmentation of natural killing activity by OK-432. Int J Immunopharmacol 3:365–375, 1981
Gooderham NJ, Mannering GJ: Depression of cytochrome P-450 and alterations of protein metabolism in mice treated with the interferon inducer polyriboinosinic acid · polyribocytidylic acid. Arch Biochem Biophys 250:418–425, 1986
Mannering GJ, Deloria LB, Abbott V: Role of xanthine oxidase in the interferon-mediated depression of the hepatic cytochrome P-450 system in mice. Cancer Res 48:2107–2112, 1988
Williams SJ, Farrel GC: Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 22:610–612, 1986
Jonkman JHG, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B, De Noord OE, Guentert TW: Effects of α-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 27:795–802, 1989
Itabashi M: Clinical utility of13C-aminopyrine breath test in patients with chronic liver diseases. Saitama Med J 18:261–268, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Itoh, S., Marutani, K. & Matsuo, S. Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with interferon-β in patients with HBeAg-positive chronic active hepatitis. Digest Dis Sci 37, 1260–1267 (1992). https://doi.org/10.1007/BF01296570
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01296570